The Mosaico clinical trial is designed to test whether an HIV vaccine will work in preventing HIV infection in healthy individuals. The goal of this study is to evaluate the immune responses of 2 HIV vaccines in men and transgender individuals who have sex with men.

Please email D’Jamel Young if you are interested in participating. 

Covid-19 Related studies

The mRNA-1273 vaccine is being developed to prevent COVID-19. The purpose of this study is to test Moderna’s vaccine candidate to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives. The mRNA-1273 vaccine is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid (mRNA), a genetic code that tells cells how to make protein, which helps the body’s immune system make antibodies to fight the virus. The vaccine cannot cause infection or make someone sick with COVID-19.

This study is a multi-center, prospective cohort study that will try to detail the clinical course of outpatient COVID-19 disease, including detailed evaluations of the viral kinetics and immunological characteristics of early infection. This information will be analyzed by measuring response rates and virus levels among participants using blood, urine, and nasal swab samples.

Screening Survey

Interested in volunteering for a COVID-19 Prevention Clinical Study?

Completed Trial (s)

HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men.